Cancer Research

Scientists discover how melanoma invades new tissue  

9 August 2022

Scientists have discovered how melanoma skin cancer cells invade new tissues in research they hope might lead to new treatments.  A team from The Institute of Cancer Research, London discovered that melanoma cells harness a gene usually used by growing nerves to escape from their immediate area and invade new tissues.   They found that melanoma […]

Could elephant genes hold the key to avoiding cancers?

29 July 2022

Scientists modelling the cancer-suppressing p53 gene identify how the 20 different molecules unique to elephants get activated for increased sensitivity and response against carcinogenic conditions – with implications for cancer treatments in humans. Scientists from seven research institutions including the University of Oxford and the University of Edinburgh have used pioneering bioinformatic modelling to investigate […]

Mathematical modelling can explain immunotherapy responses

27 July 2022

The size of tumour and immune cell populations and their interactions over time impact outcomes to treatment. Immunotherapies that activate the immune system to seek and kill cancer cells have greatly improved outcomes for many patients with solid tumours. There is still, however, a subset of patients who do not see benefit from this type […]

eBook: Insight into the latest oncology innovation

6 May 2022

This 26-page DDW eBook, sponsored by The Jackson Laboratory, contains exclusive insight from industry experts on: How machine learning is currently used across different stages of cancer research Accelerating research: the path forward for treating rare cancers Immunotherapy challenges and the tools for research Why combination immunotherapies are one of the most exciting ATMPs being […]

Merck & Pfizer’s bladder cancer drug gets NICE approval  

12 April 2022

The National Institute for Health and Care Excellence (NICE) has overturned a previous decision where it chose not to recommend the immunotherapy BAVENCIO (avelumab) for the treatment of bladder cancer.  The decision comes after avelumab’s developers, Merck KGaA and Pfizer, appealed the prior Final Appraisal Document (FAD) by NICE. Avelumab is now recommended as a maintenance […]

This week in DDW – oncology focus

8 April 2022

DDW Deputy Editor Reece Armstrong takes a look at some of the biggest developments that took place within oncology this week (4 April – 8 April).  Scientists win award for transforming breast cancer treatment  A team of scientists from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust has won a […]

Redx collaborates with Garvan on cancer project  

7 April 2022

Biotechnology company RedX is collaborating with the Garvan Institute of Medical Research on a project investigating novel therapeutic targets in cancer-associated fibrosis.  The collaboration aims to better understand treatments that could lead to increased patient survival in currently very poorly treated highly fibrotic cancers, such as pancreatic cancer.   Redx and Garvan will work on developing […]

London research centre aims to target “undruggable” cancers  

7 April 2022

A new research centre has been established in London to help discover new approaches to treating cancer.   The Centre for Protein Degradation will be based in The Institute of Cancer Research (ICR) in London and will focus on targeted protein degradation to help researchers discover new research tools and treatments for hard-to-treat cancers.  The centre […]

Scientists win award for transforming breast cancer treatment  

5 April 2022

A team of scientists in the UK has been awarded for its work in transforming a breast cancer treatment.  The researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust were named winners of the Team Science Award from the American Association for Cancer Research (AACR).  The team was awarded […]

Interview: What an FDA approval means for immunotherapies  

28 March 2022

DDW Deputy Editor Reece Armstrong speaks to Professor Frederic Triebel, CSO of Immutep about the approval of Bristol Myers Squibb’s LAG-3 antibody and why it’s causing so much excitement in the sector.    Recently, the Food and Drug Administration (FDA) approved the first combination therapy to block the immune checkpoint receptor protein LAG-3 – a move which is […]

« Previous
Next »

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free